Analysts said Vertex Pharmaceuticals’ plan to acquire Crinetics, with Vertex described as the sole bidder, is likely to reignite investor scrutiny over whether the Boston drugmaker paid too much. The transaction is poised to be Vertex’s largest-ever deal, raising attention on valuation discipline. The report matters for shareholders because it frames the bidding process as non-competitive, which can intensify questions about premium levels and underlying asset confidence. Investors will look for clearer justification of how Crinetics’ pipeline and commercial prospects map to the price paid. Deal dynamics also carry a broader signal for the biotech M&A market, where investors increasingly want visible clinical and commercial differentiation rather than trophy-sized acquisitions without a transparent competitive bidding context.